Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Horizon Pharmaceutical: Injectable Ixabepilone Hydrochloride (5mg) passes the consistency evaluation of generic drugs
On March 26, People’s Financial News reported that Haizheng Pharmaceutical (600267) announced on March 26 that its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., has received the approval notice for the supplemental application of injectable idarubicin hydrochloride (5mg) issued by the National Medical Products Administration. This drug has passed the consistency evaluation of quality and efficacy for generic drugs. Injectable idarubicin hydrochloride is indicated for the induction of remission in adult patients with untreated acute non-lymphocytic leukemia (ANLL) and for the induction of remission in adults with relapsed and refractory ANLL, as well as for second-line treatment of acute lymphoblastic leukemia (ALL) in adults and children. The original developer is Pfizer.